“The existing problem has exposed some structural weaknesses inside the EU’s medicines source chain in addition to a significant dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides mentioned. She recommended that provide chain concerns be dealt with in an EU pharmaceutica